Innovent Biologics aiming for US$422mn Hong Kong IPO

Innovent Biologics, a Chinese biopharmaceutical firm focused on the development of drugs to combat cancer and autoimmune diseases, is aiming to raise US$422mn for its Hong Kong IPO, Reuters reported
In April, Innovent announced that it had raised $150mn in its Series E funding round, led by Capital Group Private Markets.
Reuters said that Innovent’s IPO could be Hong Kong’s largest in the biotech industry this year.
The Hong Kong government introduced new legislation in April this year to encourage early-stage pharmaceutical firms to list on the stock exchange, enabling biotech companies that have yet to turn a profit or generate revenue to go public.
See more:
Thus far, Reuters said, biotech firms listing under this legislation have not performed well, and it added that “a market rout last week drove Tencent Music Entertainment to postpone its own IPO.”
According to Reuters’ sources, Innovent has secured 10 cornerstone investors with a combined commitment to $245mn in shares despite not yet having any drugs approved for commercial sale.
The firm said on 15 October that it has received IND approval to initiate trials for a new combination therapy against various lung and liver cancers, which account for around a third of all cancer cases in China.

Featured Articles

Top 10 female executives leading Japan's charge for change

As Japan pledges a 30% target for women executives at big firms by 2030, we spotlight 10 female corporate leaders blazing a trail in the country

Top 10 most valuable unicorns in China – phones to drones

Home to the world’s most valuable unicorn, not to mention the fastest growing, China may be trailing the US on numbers, but it is catching up – and fast

Top 10 fastest-growing energy companies in the APAC region

Business Chief takes a look at the top 10 fastest-growing energy companies in the APAC region, according to rankings from S&P Global Commodity Insights

Top 10 Chief Financial Officers in India

Corporate Finance

Top 10 largest companies Malaysia and the CEOs who helm them

Leadership & Strategy

5 high-profile CEO moves across Asia-Pacific this month

Leadership & Strategy